"TBSF" Human Immunoglobulin for Intravenous Use

País: Australia

Idioma: inglés

Fuente: Department of Health (Therapeutic Goods Administration)

Ingredientes activos:

normal immunoglobulin, Quantity: 60 g/L

Disponible desde:

CSL Behring Australia Pty Ltd

Designación común internacional (DCI):

normal immunoglobulin

formulario farmacéutico:

Injection, solution

Composición:

Excipient Ingredients: maltose

Vía de administración:

Intravenous

Unidades en paquete:

50mL, 200mL

clase:

Medicine Listed (Export Only)

tipo de receta:

(S1) This Schedule is intentionally blank

indicaciones terapéuticas:

TBSF Human Immunoglobulin for Intravenous Use is indicated for replacement IgG therapy in: * primary immunodeficiency (PID) * symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. TBSF Human Immunoglobulin for Intravenous Use is indicated for immunomodulatory therapy in: * Idiopathic Thrombocytopenic Purpura (ITP), in adults or children at high risk of bleeding or prior to surgery to correct the platelet count * allogeneic bone marrow transplantation * Kawasaki disease * Guillain-Barre Syndrome (GBS).

Resumen del producto:

Visual Identification: Clear, colourless solution; Container Type: Vial; Container Life Time: 3 Years; Container Temperature: Store at 2 to 8 degrees Celsius

Estado de Autorización:

Listed (Export Only)

Fecha de autorización:

2006-03-01